维多珠单抗治疗溃疡性结肠炎:VICTORY联盟的治疗结局
该研究为VICTORY联盟的回顾性研究,纳入321例临床活动性溃疡性结肠炎患者,评估维多珠单抗的安全性和有效性。12个月临床缓解和 endoscopic 缓解的累积率分别为51%和41%,既往TNFα拮抗剂暴露与缓解概率降低相关,药物总体耐受良好。
要点
- 12个月临床缓解累积率51%, endoscopic 缓解累积率41%。
- 既往TNFα拮抗剂暴露者临床缓解概率降低(HR 0.53)。
- 严重不良事件和严重感染发生率分别为6%和4%。
核心结论
- 在这个大型真实世界队列中,维多珠单抗耐受良好并能有效实现关键临床结局。
研究设计与样本
- 回顾性审查2014年5月至2016年12月VICTORY联盟数据,纳入开始维多珠单抗治疗的临床活动性溃疡性结肠炎成人患者321例,中位随访10个月。
主要发现
- 12个月临床缓解和 endoscopic 缓解的累积率分别为51%和41%。
- 12个月无激素缓解和深度缓解的累积率分别为37%和30%。
- 采用无应答填补法,12个月临床缓解率为20%(n=64/321), endoscopic 缓解率为17%(n=35/203),无激素缓解率为15%(n=30/195),深度缓解率为14%(n=28/203)。
- 既往TNFα拮抗剂暴露与临床缓解概率降低相关(HR 0.53,95%CI 0.38-0.75)和 endoscopic 缓解概率降低相关(HR 0.51,95%CI 0.29-0.88)。
- 12个月结肠切除累积率为13%,未使用过TNFα拮抗剂者(2%)低于曾暴露者(19%)。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: We aimed to quantify the safety and effectiveness of vedolizumab (VDZ) when used for UC, and to identify predictors of response to treatment. METHODS: Retrospective review (May 2014-December 2016) of VICTORY Consortium data. Adults with follow-up after starting VDZ for clinically active UC were included. Primary effectiveness outcomes were cumulative rates of clinical remission (resolution of all UC-related symptoms) and endoscopic remission (Mayo endoscopic sub-score 0). Key secondary effectiveness outcomes included cumulative rates of corticosteroid-free remission and deep remission (clinical remission and endoscopic remission). Cox proportional hazard analyses were used to identify independent predictors of treatment effectiveness. Non-response imputation (NRI) sensitivity analyses were performed for effectiveness outcomes. Key safety outcomes were rates of serious infection, serious adverse events, and colectomy. RESULTS: We included 321 UC patients (71% prior TNFα antagonist exposure, median follow-up 10 months). The 12-month cumulative rates of clinical remission and endoscopic remission were 51% and 41%, respectively. Corresponding rates for corticosteroid-free remission and deep remission were 37% and 30%, respectively. Using NRI, 12-month rates were 20% (n = 64/321) for clinical remission, 17% (n = 35/203) for endoscopic remission, 15% (n = 30/195) for corticosteroid-free remission, and 14% (n = 28/203) for deep remission. A majority of the patients without adequate follow-up at 12 months who were deemed non-responders using NRI had already achieved clinical remission (n = 70) or a significant clinical response (n = 36) prior to 12 months. VDZ discontinuation prior to 12 months was observed in 91 patients, for lack of response (n = 56), need for surgery (n = 29), or adverse event (n = 6). On multivariable analyses, prior exposure to a TNFα antagonist was associated with a reduced probability of achieving clinical remission (HR 0.53, 95% CI 0.38-0.75) and endoscopic remission (HR 0.51, 95% CI 0.29-0.88). Serious adverse events and serious infections were reported in 6% and 4% of patients, respectively. Overall cumulative rates of colectomy over 12 months were 13%, with lower rates observed in patients naive to TNFα antagonist therapy (2%) than those who had been exposed to TNFα antagonists (19%). CONCLUSION: In this large real-world cohort we observed that VDZ was well tolerated and effective in achieving key clinical outcomes.
引用
- Narula N, Peerani F, Meserve J, et al. Vedolizumab for Ulcerative Colitis: Treatment Outcomes from the VICTORY Consortium. Am J Gastroenterol. 2018. PMID: 29946178. doi:10.1038/s41395-018-0162-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。